Pembrolizumab Biosimilar (NeuClone/Serum Institute of India)

帕博利珠单抗生物类似药（NeuClone/Serum Institute of India）

Report date: 2025/02/18 10:50:00

Base Information

Drug NamePembrolizumab Biosimilar (NeuClone/Serum Institute of India)
Drug Alias NameN/A
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionProgrammed cell death protein 1 blockers
TargetsProgrammed cell death protein 1
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryAustralia
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesNeucloneSerum Institute Of India Ltd
China Registration ClassN/A

Develop Information

Active CompaniesNeucloneSerum Institute Of India Ltd
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A